Hims & Hers Health, Inc.
HIMSNYSE
$32.84
↓ -2.5%Jul 17 close · end-of-day
Price
1Y↓ -36.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.5B
Enterprise Value
$6.7B
P/E
—
P/S
3.2
P/B
16.8
EV/EBITDA
179.6
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$2.4B
Net Income (TTM)
-$13.2M
Free Cash Flow (TTM)
—
Gross Margin
71.7%
Operating Margin
-1.3%
Net Margin
-0.6%
ROE
-3.0%
ROIC
—
Debt / Equity
—
Net Cash
$750.9M
Return 1Y
-34.3%
Company profile
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category. In addition, it offers medical consultation services and health and wellness products through wholesale partners.
- CEO
- Andrew Dudum
- Sector
- Services
- Industry
- Healthcare
- Employees
- 650
- Headquarters
- California
- Website
- forhims.com
Management & directors
- Okupe OluyemiChief Financial Officer
- Carroll Patrick HarrisonChief Medical Officer
- Becklund IrenePAO
- Chi MichaelChief Commercial Officer
- Elshenawy MohamedCTO
- Autor Deborah M.Chief Policy Officer
- Boughton SoleilChief Legal Officer
- Dudum AndrewChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
HIMS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$608.1M↑ +3.8%
Diluted EPS-$0.40↓ -300.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $148.8M | $271.9M | $526.9M | $872.0M | $1.5B | $2.3B |
| Gross profit | $109.5M | $204.5M | $408.7M | $714.9M | $1.2B | $1.7B |
| Operating income | -$15.1M | -$115.0M | -$68.7M | -$29.5M | $61.9M | $105.6M |
| Net income | -$18.1M | -$107.7M | -$65.7M | -$23.5M | $126.0M | $128.4M |
| Diluted EPS | -$0.51 | -$0.58 | -$0.32 | -$0.11 | $0.53 | $0.51 |
| Operating cash flow | -$2.5M | -$34.4M | -$26.5M | $73.5M | $251.1M | $300.0M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | 73.6% | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% |
| Operating margin | -10.2% | -42.3% | -13.0% | -3.4% | 4.2% | 4.5% |
| Net margin | -12.2% | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $315.6M | $401.6M | $481.1M | $586.0M | $544.8M | $599.0M | $617.8M | $608.1M |
| Gross profit | $256.6M | $317.9M | $369.5M | $430.7M | $416.2M | $442.1M | $444.4M | $396.8M |
| Operating income | $11.0M | $22.4M | $18.6M | $57.9M | $26.7M | $11.8M | $9.2M | -$78.3M |
| Net income | $13.3M | $75.6M | $26.0M | $49.5M | $42.5M | $15.8M | $20.6M | -$92.1M |
| Diluted EPS | $0.06 | $0.32 | $0.10 | $0.20 | $0.17 | $0.06 | $0.08 | -$0.40 |
| Operating cash flow | $53.6M | $85.3M | $86.4M | $109.1M | -$19.1M | $148.7M | $61.3M | $89.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 81.3% | 79.2% | 76.8% | 73.5% | 76.4% | 73.8% | 71.9% | 65.2% |
| Operating margin | 3.5% | 5.6% | 3.9% | 9.9% | 4.9% | 2.0% | 1.5% | -12.9% |
| Net margin | 4.2% | 18.8% | 5.4% | 8.4% | 7.8% | 2.6% | 3.3% | -15.1% |
Company news
Jul 17, 2026
Jul 14, 2026
Jul 13, 2026
- 7d agoHims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026finance.yahoo.com
- 7d ago1 Stock Under $50 with Exciting Potential and 2 Facing Challengesfinance.yahoo.com
- 7d agoIs Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?finance.yahoo.com
- 7d agoHIMS Stock Logs Worst Week In 2 Months — Turns To Peptides Campaign Ahead Of Key FDA Meetingstocktwits.com
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Okupe Oluyemi· Chief Financial Officer | Sale | 7,163 | $36.49 | $261,351.37 | filing |
| 2026-07-06 | Okupe Oluyemi· Chief Financial Officer | Option exercise | 7,163 | $5.01 | $35,886.63 | filing |
| 2026-06-22 | Okupe Oluyemi· Chief Financial Officer | Sale | 18,197 | $34.03 | $619,216.61 | filing |
| 2026-06-22 | Okupe Oluyemi· Chief Financial Officer | Option exercise | 6,376 | $5.01 | $31,943.76 | filing |
| 2026-06-18 | Carroll Patrick Harrison· Chief Medical Officer | Sale | 23,726 | $35.00 | $830,410.00 | filing |
| 2026-06-17 | Elshenawy Mohamed· CTO | Sale | 30,040 | $31.50 | $946,260.00 | filing |
| 2026-06-17 | Chi Michael· Chief Operating Officer | Sale | 14,027 | $31.50 | $441,850.50 | filing |
| 2026-06-17 | Becklund Irene· PAO | Sale | 4,490 | $31.50 | $141,435.00 | filing |
| 2026-06-16 | Becklund Irene· PAO | Sale | 7,573 | $30.25 | $229,083.25 | filing |
| 2026-06-15 | Elshenawy Mohamed· CTO | Tax withholding | 151,534 | $30.17 | $4.6M | filing |
| 2026-06-15 | Dudum Andrew· Chief Executive Officer | Tax withholding | 85,632 | $30.17 | $2.6M | filing |
| 2026-06-15 | Chi Michael· Chief Operating Officer | Tax withholding | 47,699 | $30.17 | $1.4M | filing |
| 2026-06-15 | Okupe Oluyemi· Chief Financial Officer | Tax withholding | 39,541 | $30.17 | $1.2M | filing |
| 2026-06-15 | Boughton Soleil· Chief Legal Officer | Tax withholding | 23,315 | $30.17 | $703,413.55 | filing |
| 2026-06-15 | Autor Deborah M.· Chief Policy Officer | Tax withholding | 15,396 | $30.17 | $464,497.32 | filing |
| 2026-06-15 | Carroll Patrick Harrison· Chief Medical Officer | Tax withholding | 8,310 | $30.17 | $250,712.70 | filing |
| 2026-06-15 | Becklund Irene· PAO | Tax withholding | 5,870 | $30.17 | $177,097.90 | filing |
| 2026-06-15 | Manuel Anja | Option exercise | 10,040 | — | — | filing |
| 2026-06-15 | Carroll Patrick Harrison· Chief Medical Officer | Option exercise | 25,926 | — | — | filing |
| 2026-06-15 | Okupe Oluyemi· Chief Financial Officer | Option exercise | 71,616 | — | — | filing |
| 2026-06-15 | Autor Deborah M.· Chief Policy Officer | Option exercise | 32,919 | — | — | filing |
| 2026-06-15 | Chi Michael· Chief Operating Officer | Option exercise | 86,264 | — | — | filing |
| 2026-06-15 | Becklund Irene· PAO | Option exercise | 15,971 | — | — | filing |
| 2026-06-15 | Boughton Soleil· Chief Legal Officer | Option exercise | 42,261 | — | — | filing |
| 2026-06-15 | Dudum Andrew· Chief Executive Officer | Option exercise | 154,991 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.